


LT175

Cat. No.:	HY-121900		
CAS No.:	862901-87-9		
Molecular Formula:	C ₂₁ H ₁₈ O ₃		
Molecular Weight:	318.37		
Target:	PPAR		
Pathway:	Cell Cycle/DNA Damage; Vitamin D Related/Nuclear Receptor		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (314.10 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
Preparing Stock Solutions	1 mM	3.1410 mL	15.7050 mL	31.4100 mL
	5 mM	0.6282 mL	3.1410 mL	6.2820 mL
	10 mM	0.3141 mL	1.5705 mL	3.1410 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (7.85 mM); Clear solution; Need ultrasonic Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (7.85 mM); Clear solution; Need ultrasonic Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (7.85 mM); Clear solution; Need ultrasonic 			

BIOLOGICAL ACTIVITY

Description	LT175, a dual PPARα/γ ligand, is an orally active partial agonist against PPARγ (hPPARα:EC ₅₀ =0.22 μm; mPPARα:EC ₅₀ =0.26 μm; hPPARγ:EC ₅₀ =0.48 μm). LT175 interacts with PPARγ and affects the recruitment of the coregulators cyclic-AMP response element-binding protein-binding protein and nuclear corepressor 1 (NCoR1). LT175 interacts with PPARγ in a hydrophobic region called “diphenyl pocket”. LT175 has potent insulin-sensitizing effects and reduced adipogenic properties ^[1] .		
IC₅₀ & Target	hPPARα 0.22 μM (EC50)	mPPARα 0.26 μM (EC50)	hPPARγ 0.48 μM (EC50)

In Vivo

LT175 (100 mg/kg/day; orally; for 3 days) induces a significant decrease in body weight (11%) and reduces fasting blood glucose, triglycerides, and free fatty acids. LT175 decreases total plasma cholesterol significantly in diet-induced Insulin-resistant mice (six-week-old C57Bl/6J male mice)^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Federica Gilardi, et al. LT175 is a novel PPAR α / γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties. J Biol Chem. 2014 Mar 7;289(10):6908-6920.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA